We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sareum Holdings Plc | SAR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.50 | 1.59% | 32.00 | 08:39:19 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 31.50 | 31.50 | 32.00 | 32.00 | 31.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/7/2024 19:19 by criticalthinker1 Are they?I mean we've had disruption here. Plain and simple and 'maybe' justified...however, it came to my attention along time ago that Sareum were a 'target'... Remember the poster Puma...loved following RiverFort along with Maj...look at all the companies they 'assisted'...similar stories.... Well here's something or nothing re RiverFort and Puma Investments ...just a coincidence...but lots of individual investors are becoming aware of how corruption in the markets seem to have a free ride...along with two names...Riverfort and Puma How does Riverfort Global's Market Cap benchmark against competitors? We've identified the following companies as similar to Riverfort Global Opportunities PLC because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below. Riverfort Global's Market Cap Benchmarks Name Market Cap Gledhow Investments PLC 416.206 K Blue Star Capital Plc 1.12 M Hermes Pacific Investments PLC 1.225 M Riverfort Global Opportunities PLC 1.706 M Coinsilium Group Ltd 4.675 M Sure Ventures PLC 7.071 M Puma Alpha VCT plc 30.709 M Volvere PLC 32.174 M Hydrogenone Capital Growth PLC 66.6 M Mobeus Income And Growth Vct Plc 86.888 M Financials 201.3 M Literacy Capital PLC 309.9 M Now would that be the Puma company that has a 'performance' fee of 20%... You can read up about Puma InvestVCT13 at your own leisure...but imo it seems to be an internal directory of corruption with Individuals who are in a position to rub my back your back scenario ....seems they had their claws in the mhra too with employees...chap I know resigned from the NHS...very high position...basically Be lovely if an independent journalist got wind of this ( yes I've posted this and extra to a journalist who is looking into it with interest) All best Steadydanny 👌 |
Posted at 20/7/2024 17:49 by criticalthinker1 Wolf a narcissistic individual/sociopath deflects by justifying their opinion by talking surreptitiously about something that is deflection, which is actual deflection from the actual topic that should be discussed. You fit within that profile. Hence I called you out and engaged to get your responses so that others could see it on here despite others advising differently.I stand my ground! Anyhow, good post on lse re SRA737. I hope that they are paying attention to what I posted about SRA737 back along as a monotherapy. Please see below from Science Direct 19.7.24. As I advised DO NOT dismiss SRA737 as a monotherapy as it gives an early start on multiple biomarkers....such as amongst the many...ovarian and endometrial....which then other holders of certain drugs (maybe patents coming to an end) think ...oh hang on let's try our drug with this SRA737 that as a monotherapy proves it can bind with other drugs to be more effective....hence their drug becomes 'reborn' . In summary, we observed impressive single agent SRA737 activity in CCNE1amp PDX models, and the CHK1i/PARPi combination was synergistic in CCNE1amp cell lines, with a trend for a difference with the CHK1i/PARPi combination in vivo, with lack of statistical significance seen, with the same dosing regimen as that which was more successful in HRD models. Validated biomarkers for predicting response to CHK1 inhibition, for example, denoting high replication stress (i.e., CCNE1amp, MYCN), would be highly valuable and the use of SRA737, especially as monotherapy, should be considered early in the disease course. Hence, SRA737 is a potent, highly selective, orally bioavailable CHK1i that demonstrated activity in PARPi-sensitive, acquired PARPi-resistant BRCA1/2MUT and platinum-resistant CCNE1amp preclinical HGSOC cancer models. These findings support urgent exploration in clinical trials of such aggressive HGSOC types, given an improved chance of combination tolerability with SRA737. When you join the dots as I've mentioned on here despite being ridiculed I made this information of where this drug was going way back...but that's why disruptors are employed...and even significant holders wish to ignore my postings. OK... Not fussed. I invested here for a reason, with others. Let's keep this above the radar so we don't have a Sierra Oncology moment and we can putport that investors were aware of the potential by posts that last for perpetuity so any underhanded shenanigans will have to deal with the them. All best Steadydanny Nb. The science guys who developed SRA737 are getting fantastic results from 1801 which dovetails into 1802.... via translational studies. Certain individuals moved on from SIERRA ONCOLOGY and still we are led to believe it was all about momontelieb.... Never ever in a month of Sundays does that hold water. |
Posted at 10/7/2024 07:41 by wolfofwallstreets Tim stepping down..No explanation given.. Smells like more bad news to me.. Probs can't afford to pay a full time salary... Can't keep rinsing the investors forever.. If this was good news..some explanation would be given... |
Posted at 05/7/2024 14:19 by peaceandlove Indeed a sobering post, but also very correct in respect of where this company is right now.The poster is correct regarding big deals etc. In my opinion, there're no license or takeover deals on the horizon. The excitement of a Phase 1 clinical trial was in my opinion very over optimistic particularly when the happy clappers are ramping that large pharmaceuticals are wanting in. The ramping was ridiculous with so many posters talking up the value of £billion pound deals and comparing Sareum to successful companies that have made £billions. Perhaps it's because large pharmaceutical believe it's not very good? I could be wrong, but there is absolutely no evidence of deals. If you invested 5 days ago you'd be down over 30%! In addition, a few kept comparing 2021 to now? It's so annoying and to be blunt nonsense talk. Different economic conditions and circumstances! As you say, I've said many times a Phase 1 trial assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. The problem now for this company is raising funds to start with a Phase 2a, which I suspect will be towards the end of the year or early next year. There is no doubt in my mind that dilution is on it's way, which will be very detrimental to shareholders. However, it is the only way forward. I don't see a partnership etc. It never ends. Some have been here for 15 years!!!!! Investors have been promised again and again and the share price plummet's again and again (less than 1p old money). We don't even know if the drug works? Sareum state "our approach is to discover and develop programmes to late pre clinical, or early clinical, stages before licensing or partnering, maximising the return on our investment". Well this goal is clearly not being met. Wonder why? Have a good weekend! 👍 |
Posted at 05/7/2024 07:28 by wolfofwallstreets The tide is turning...Yes it is.. And sareum investors are in the water as titanic just sank.. |
Posted at 30/5/2024 20:37 by wolfofwallstreets Another boring irrelevant stupid post from criticalstinker...Do you not think investors can read RNS themselves you moron. Do.yoi think people need to.to explain "now" hahaha Actually.. the reading level of most thicko sareum investors is magazines .. They are sacking brokers as they head into oblivion.. |
Posted at 29/4/2024 17:16 by peaceandlove It's all "ifs, buts and maybes" over at LSE. The share price got to 38p last Wednesday. I repeatly stated it was a pump and dump. The smart investors sold and moved on. You can see the herd has left for pastures new. The not so smart investors (LTH's) are still invested spouting nonsense about £300million here a £billion there LOL particularly SOG who stated earlier today, he felt the share price will reach 45p-50p by the end of the week. A 100% rise from now. Wishful thinking SOG. Perhaps another break for you me thinks.Saftey data for 1801 will give the share price a shot in the name - that's all - maybe reach 50p if lucky before a falling back. People forget 1801 has not be proven to work as of yet. Did you see the link I put up earlier today. TM was talking up licensing deals in June 2020. Sareum Holdings remains a massive gamble. I personally do not feel they'll ever licence their products. All talk and no action. |
Posted at 09/4/2024 22:08 by criticalthinker1 Very on point by the investor on lse who has posted 3 times in 13 years!Twice this evening! They imo are obviously aware of the very poor decisions that have been made when given the recent fundraiser this could have been done when we were at £2.50 ish. This is more than mismanagement by poor decision making acumen given the vitriol we are served about the cvs of appointed individuals to guide the scientific individuals...this is a British company researching drugs for the betterment of society backed by small private investors who have not only been bent over...but the affiliation with CRUK comes into play. Let's not hope this reaches the papers like Sirius Minerals and the marketing they did to get the locals involved which effectively sold out to Anglo American with deep ties to Qatar and the reserves of potash that will be destined to re green elsewhere apart from our green and pleasant land...which is and will be a very similar story that garners attention such as the Post Office/Fujitsu/Horiz Just imagine if a hit job was undertaken on a promising drug development company but it was put on a few years project by a larger pharma with certain assistance to divide the support and hope people forgot...and then it got 'rescued'. EGM NEEDED ASAP. |
Posted at 30/3/2024 22:24 by peaceandlove I honestly think the MHRA didn't authorise Sareum's clinical trial because they felt that the novel formulation isn't a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. In addition, if anyone noticed at the time, Sareum's website stated "the company admits that to go forward through and beyond the Phase 1 trial, it will have to go back to investors to raise more money". This is why I wouldn't trust SOG and Co as far as I could throw them. The happy clappers only state the points that favour Sareum. Not once have they uploaded evidence that Sareum's products are ahead of competitors. SOG and all the happy clappers are small time investors that have gambled their money into a small bio hoping and actually convincing themselves that they're going to be rich. Wolf, they're of their nuts 😆🤣 All of them talk more nonsense than David Icke 😆Seriously, you mark this post when I say I told you so. Unfortunately, more people will invest their hard working money into this company hoping that this is the right one, I'm afraid in my honest opinion this won't come true. However, I expect they'll carry on ramping to the bitter end. Absolute madness!!!!!! Ignore CS, he's on the special brew again. Poor fella. Happy Easter 🐣 |
Posted at 16/3/2024 19:51 by criticalthinker1 OK Wolf. That's a fair shout.But I think it is only fair that investors understand the individuals that Sareum investors are paying for to represent us. I suggest all investors do their own due diligence on the employees of Peel Hunt (and affiliates)and if they feel they have appropriate skill sets. Check it out on LinkedIn Ella Hastings Benjamin Harris Matt Hoole Anup Das Rob Parker Edward Lowe Tom Graham Find Nugent Paul Shackleton Josh Harvey Plenty more I can post but it all stems back to Mr Steel and a certain Mr Parkers affiliations with a previous Peel Hunt employee! Are they worth your SIPPS security? Are they worth our fee? Are they worth our IR dealings? Do they work for the lowly shareholders or someone else. More I can say and blow this right open. Opportunity for the board to step up. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
